Fenofibrate A peroxisome proliferator activated receptor-α agonist treatment ameliorates Concanavalin A-induced hepatitis in rats

Peroxisome proliferator-activated receptor-α (PPARα) is physiologically highly expressed by hepatocytes, where it plays a pivotal anti-inflammatory and metabolic role. The decrease expression and functional activity of PPARα in hepatocytes during hepatitis C virus infection may contribute to the pat...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2013-12, Vol.721 (1-3), p.35-42
Main Authors: Mohamed, Doaa I., Elmelegy, Ahmed A.M., El-Aziz, Lubna F.A., Abdel kawy, Hala S., El-Samad, Abeer A. Abd, El-Kharashi, Omnyah A.
Format: Article
Language:English
Subjects:
actin
agonists
alanine
Alanine Transaminase - blood
Animals
apoptosis
Aspartate Aminotransferases - blood
aspartic acid
Biomarkers - metabolism
blood serum
Concanavalin A
Concanavalin A - pharmacology
Factor alpha
Fenofibrate
Fenofibrate - pharmacology
Fenofibrate - therapeutic use
fibrosis
hepatitis
Hepatitis - drug therapy
Hepatitis - etiology
Hepatitis - metabolism
Hepatitis - pathology
Hepatitis C virus
hepatocytes
histopathology
humans
immunohistochemistry
inflammation
liver
Liver - blood supply
Liver - drug effects
Liver - metabolism
Liver - pathology
Male
Malondialdehyde
Malondialdehyde - metabolism
muscles
Oxidative Stress - drug effects
pathogenesis
pharmacology
Portal pressure
Portal Pressure - drug effects
PPAR alpha - agonists
PPARα
Rats
Rats, Wistar
transaminases
Tumor necrosis
tumor necrosis factor-alpha
Tumor Necrosis Factor-alpha - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peroxisome proliferator-activated receptor-α (PPARα) is physiologically highly expressed by hepatocytes, where it plays a pivotal anti-inflammatory and metabolic role. The decrease expression and functional activity of PPARα in hepatocytes during hepatitis C virus infection may contribute to the pathogenesis of the disease in humans. This study aims at evaluating the effects of PPARα activation with fenofibrate (FF) on liver inflammation, fibrosis and portal pressure (PP) in Concanavalin A (Con A)- induced hepatitis in rats. The rats were randomly divided to 3 groups; control (1ml saline iv/wk) group, Con A (20mg/kg/iv/wk) group and Con A with FF (100mg/kg/day p.o) group. Blood samples and livers were collected by the end of the first, second, fourth and eighth injections of Con A for biochemical, histopathological and immunohistochemistry studies for α-smooth muscle actin (α SMA). Measurement of PP was performed by the end of the 8th week. FF group had a significant (P
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2013.09.058